Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Evommune, Inc. (NYSE:EVMN) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $45.6250.

Several equities analysts have issued reports on EVMN shares. HC Wainwright cut Evommune from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada reissued an “outperform” rating and issued a $48.00 price target on shares of Evommune in a report on Friday, April 10th. Raymond James Financial downgraded Evommune from a “strong-buy” rating to a “moderate buy” rating in a research note on Monday, June 29th. William Blair lowered Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Finally, Wall Street Zen cut Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th.

Evommune Stock Performance

Shares of EVMN opened at $11.60 on Tuesday. The stock has a market capitalization of $417.84 million and a P/E ratio of -1.22. Evommune has a 1 year low of $11.15 and a 1 year high of $33.20. The company’s fifty day moving average is $19.01 and its two-hundred day moving average is $21.80.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Sell-side analysts predict that Evommune will post -2.83 EPS for the current year.

Insider Buying and Selling at Evommune

In other news, insider Jeegar Pravinkumar Patel sold 16,687 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $22.74, for a total transaction of $379,462.38. Following the transaction, the insider directly owned 46,403 shares of the company’s stock, valued at $1,055,204.22. This represents a 26.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kyle Carver sold 18,175 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $22.84, for a total transaction of $415,117.00. Following the completion of the sale, the chief financial officer owned 59,335 shares of the company’s stock, valued at $1,355,211.40. This trade represents a 23.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 100,854 shares of company stock worth $2,279,142. Company insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Evommune

Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in Evommune in the 4th quarter valued at approximately $34,000. Strs Ohio purchased a new stake in Evommune during the first quarter worth $41,000. The Manufacturers Life Insurance Company acquired a new stake in Evommune in the fourth quarter valued at $179,000. XTX Topco Ltd acquired a new stake in Evommune in the fourth quarter valued at $321,000. Finally, Oxford Asset Management LLP purchased a new position in shares of Evommune in the fourth quarter valued at $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.